This profile was last updated on 5/1/13
and contains information from public web pages and contributions from the ZoomInfo community.
|
Dr. Diane YoungWrong Dr. Diane Young? |
|
Background
Employment History
-
Vice President and Global Head of Clinical Development
Novartis AG
-
Vice President of Medical Affairs
Novartis AG
Education
-
MD
-
M.D.
105 Total References
Web References
PTCommunity.com - Daily News Briefing
www.pharmscope.com, 5 June 2005 [cached]"The effectiveness of Gleevec in these five diseases further underscores how cancers and diseases of different origin and location can share common pathways that often respond to the same targeted treatment," said Diane Young, MD, Vice President and global head of Clinical Development at Novartis Oncology.
www.pharmscope.com, 5 June 2005 [cached]
Board of Trustees
www.thevaleriefund.org, 21 April 2012 [cached]Diane Young, M.D. - Novartis
Click here to read biography
Diane Young, M.D., Novartis
Diane is currently the Vice President of Clinical Development at Novartis Oncology.
In this position, she leads a global group of clinical research personnel and oversees the development of a diverse pipeline of oncology and hematology products, including targeted therapies, cytotoxic chemotherapy, and iron chelation therapy.
She has pursued her career in research in the pharmaceutical industry for eighteen years, with positions of increasing responsibility at Hoffman-La Roche, Sandoz, and Johnson and Johnson, prior to joining Novartis.
www.thevaleriefund.org, 21 April 2012 [cached]
EORTC Study: Progression-free survival improves for 800 mg vs. 400 mg patients
www.liferaftgroup.com, 4 April 2009 [cached]"This latest study provides further evidence that Gleevec is a highly effective therapy for patients with advanced Kitpositive GIST, and offers insight into potential ways to improve long-term outcomes for these patients," said Diane Young, Vice President and global head of Clinical Development at Novartis Oncology.
www.liferaftgroup.com, 4 April 2009 [cached]
Media releases
www.novartis.com, 13 June 2008 [cached]"Our robust clinical program with Glivec continues to provide meaningful insights into the treatment of Ph+ CML and other types of cancer," said Diane Young, MD, Head of Global Medical Affairs at Novartis Oncology.
www.novartis.com, 13 June 2008 [cached]
Board of Trustees - The Valerie Fund
www.thevaleriefund.org, 30 Oct 2009 [cached]Diane Young, M.D., Novartis
Diane Young, M.D., Novartis
Diane Young is currently the Vice President of Clinical Development at Novartis Oncology.
In this position, she oversees the development of a diverse pipeline of oncology and hematology products, including targeted therapies, cytotoxic chemotherapy, iron chelation therapy, and others.
She leads a global group of clinical research personnel.She has pursued her career in research in the pharmaceutical industry for eighteen years, with positions of increasing responsibility at Hoffman-La Roche, Sandoz, and Johnson and Johnson, prior to joining Novartis.
www.thevaleriefund.org, 30 Oct 2009 [cached]
...
Other People with the name "Young":
Otterburn Legal Consulting LLP
Texas Harley-Davidson
UK Stem Cell Bank holdings
Saint Andrews
Greater Norfolk Corporation
Copyright © 2013 Zoom Information, Inc. All rights reserved
Pro2013_Iteration7.207[03] SEIDXWK-21